Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75478
UPID:
TAD2A_HUMAN
Alternative names:
Transcriptional adapter 2-like
Alternative UPACC:
O75478; A8MVD0; B3KMU9; Q9BVJ0; Q9UCW2; Q9UP49
Background:
Transcriptional adapter 2-alpha, also known as Transcriptional adapter 2-like, is a pivotal component of the ATAC complex, exhibiting histone acetyltransferase activity on histones H3 and H4. It plays a crucial role in transcription activation, DNA binding, and chromatin remodeling. This protein is instrumental in enhancing TP53/p53 'Lys-321' acetylation, leading to diminished TP53 stability and transcriptional activity, and it also facilitates XRCC6 acetylation, aiding cell apoptosis in response to DNA damage.
Therapeutic significance:
Understanding the role of Transcriptional adapter 2-alpha could open doors to potential therapeutic strategies.